Ying Du Sells 50,000 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $20.09, for a total transaction of $1,004,500.00. Following the transaction, the chief executive officer directly owned 1,122,626 shares in the company, valued at $22,553,556.34. This represents a 4.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ying Du also recently made the following trade(s):

• On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The shares were sold at an average price of $20.45, for a total transaction of $54,253.85.
• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total transaction of $113,694.64.

Zai Lab Stock Up 1.3%

NASDAQ:ZLAB traded up $0.26 during trading hours on Friday, hitting $20.59. 903,109 shares of the stock traded hands, compared to its average volume of 767,050. Zai Lab Limited Unsponsored ADR has a 1 year low of $15.96 and a 1 year high of $44.34. The company has a market cap of $2.34 billion, a price-to-earnings ratio of -12.71 and a beta of 0.85. The stock has a 50 day moving average price of $20.31 and a 200 day moving average price of $19.82.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. The firm had revenue of $99.61 million for the quarter. Equities analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zai Lab

A hedge fund recently raised its stake in Zai Lab stock. SG Americas Securities LLC increased its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Wall Street Analysts Forecast Growth

ZLAB has been the topic of several analyst reports. Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. Cantor Fitzgerald reduced their price objective on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Weiss Ratings cut shares of Zai Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. JPMorgan Chase & Co. reduced their price objective on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Finally, Zacks Research cut shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Zai Lab currently has an average rating of “Moderate Buy” and an average target price of $45.83.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.